BioCentury | Apr 8, 2021
Distillery Therapeutics

Camptothecin-carrying bioadhesive nanoparticles for skin cancer

DISEASE CATEGORY: Cancer INDICATION: Skin cancer A Yale University team showed that bioadhesive nanoparticle delivery of topoisomerase inhibitor camptothecin could treat squamous cell carcinoma. The nanoparticle therapy was created by incubating non-adhesive hyperbranched polyglycerol-based nanoparticles...
BioCentury | Apr 8, 2021
Distillery Therapeutics

PON-2 identified as B cell-ALL target

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL) Inhibiting PON2, a lactonase, could treat B cell ALL (B-ALL). Levels of PON2 mRNA were higher in Philadelphia chromosome-positive B-ALL cells from patients than in normal pre-B cells,...
BioCentury | Apr 8, 2021
Distillery Therapeutics

Folate receptor-targeting CAR T for ovarian and other cancers

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer; melanoma; colorectal cancer CAR T cells targeting folate receptor FOLR2 could treat ovarian cancer, melanoma and colorectal cancer. Among patients with stage III or IV ovarian cancer, high FOLR2...
BioCentury | Apr 7, 2021
Distillery Therapeutics

eIF4E identified as target in obesity, fatty liver disease

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; liver disease Reducing levels of eIF4E or lowering the RNA cap-binding protein’s activity by blocking its phosphorylation could treat obesity...
BioCentury | Apr 7, 2021
Distillery Therapeutics

A targeted CDK12 degrader for ALL

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL) A CDK12-targeted degrader, designed by a Dana-Farber Cancer Institute and Harvard Medical School team co-led by Nathanael Gray, could treat T cell ALL. The degrader’s targeting moiety was derived...
BioCentury | Apr 7, 2021
Distillery Therapeutics

CXCR4 antagonist identified for hepatocellular carcinoma

DISEASE CATEGORY: Cancer INDICATION: Liver cancer An oxopropylaminoacetic acid-based CXCR4 antagonist could treat hepatocellular carcinoma (HCC). The CXCR4 inhibitor, optimized from a compound the...
BioCentury | Apr 7, 2021
Distillery Therapeutics

Toxin-derived YBX1 inhibitor for ovarian cancer

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer A YBX1 inhibitor derived from azopodophyllotoxin could treat ovarian cancer. In a panel of five human ovarian cancer cell lines, the compound inhibited growth with IC50 values of 1.27-6.8...
BioCentury | Apr 7, 2021
Distillery Therapeutics

RECK, an inhibitor of amyloid precursor protein cleavage, as a target for Alzheimer’s

DISEASE CATEGORY: Neurology INDICATION: Alzheimer’s disease Blocking RECK, a membrane-tethered inhibitor of APP-cleaving enzyme ADAM10, could treat Alzheimer’s disease. Levels of membrane-tethered...
BioCentury | Apr 6, 2021
Distillery Therapeutics

A UTI vaccine that stimulates Th1 T cell responses

DISEASE CATEGORY: Infectious disease INDICATION: Urinary tract infection (UTI); Escherichia A vaccine containing uropathogenic E. coli antigens and an adjuvant that promotes Th1 immune responses could prevent UTIs. Mice immunized via intrabladder delivery of a lysate...
BioCentury | Apr 6, 2021
Distillery Therapeutics

A neutralizing mAb against Junin virus for Argentine hemorrhagic fever

DISEASE CATEGORY: Infectious disease INDICATION: Viral hemorrhagic fever A mAb targeting Junin virus glycoprotein could treat infections by Junin virus, which causes Argentine hemorrhagic fever. In monkey kidney epithelial cells, a humanized mAb against Junin virus...
Items per page:
1 - 10 of 18280